Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1
Artículo
![Thumbnail](/themes/Mirage2/images/cubierta.jpg)
Publication date
2014Metadata
Show full item record
Cómo citar
Valdés, Pamela
Cómo citar
Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1
Author
Abstract
Parkinson disease (PD) is characterized by the selective loss of
dopaminergic neurons of the substantia nigra pars compacta
(SNpc). Although growing evidence indicates that endoplasmic reticulum
(ER) stress is a hallmark of PD, its exact contribution to the
disease process is not well understood. Here we report that developmental
ablation of X-Box binding protein 1 (XBP1) in the nervous
system, a key regulator of the unfolded protein response (UPR),
protects dopaminergic neurons against a PD-inducing neurotoxin.
This survival effect was associated with a preconditioning condition
that resulted from induction of an adaptive ER stress response
in dopaminergic neurons of the SNpc, but not in other
brain regions. In contrast, silencing XBP1 in adult animals triggered
chronic ER stress and dopaminergic neuron degeneration.
Supporting this finding, gene therapy to deliver an active form of
XBP1 provided neuroprotection and reduced striatal denervation in
animals injected with 6-hydroxydopamine. Our results reveal
a physiological role of the UPR in the maintenance of protein
homeostasis in dopaminergic neurons that may help explain the
differential neuronal vulnerability observed in PD.
General note
Artículo de publicación ISI
Patrocinador
This work was funded primarily by the Michael J. Fox
Foundation for Parkinson’s Research, Fondo de Fomento al Desarrollo Científico
y Tecnológico D11I1007, Millennium Institute P09-015-F, Fondo Nacional
de Desarrollo Científico y Tecnológico (FONDECYT) 1140549 (to C.H.),
FONDECYT 3120146 (to G.M.), Comisión Nacional de Investigación Científica
y Tecnológica (CONICYT) Capital Humano en la Academia 7912010006 (to
R.L.V.), and Ring Initiative ACT1109 (to C.H. and F.A.C.). Funding was also
provided by Comité de Evaluación y Orientación de la Cooperación Científica
con Chile del Gobierno de Francia-CONICYT C13S02, CONICYT Grant
USA2013-0003, the Muscular Dystrophy Association, the ALS Therapy Alliance,
and the Alzheimer Association (C.H.). P.V., C.M., and A.M. are doctoral
fellows supported by a CONICYT fellowship and CONICYT Research Grant AT-
24100179). F.A.C. is supported by FONDECYT 1110987 and Millennium Nucleus
P07-011-F. B.L.S. is supported by the Swiss National Science Foundation
(Grant 31003A_135696).
Quote Item
PNAS | May 6, 2014 | vol. 111 | no. 18
Collections